Application value of minocycline capsule combined with recombinant bovine basic fibroblast growth factor on patients with rosacea based on changes of skin barrier function and DLQI score
Application value of minocycline capsule combined with recombinant bovine basic fibroblast growth factor on patients with rosacea based on changes of skin barrier function and DLQI score
Objective To explore the application value of minocycline capsule combined with recombinant bovine basic fibroblast growth factor(rb-bFGF)on patients with rosacea based on changes of skin barrier function and dermatology life quality index(DLQI)score.Methods A total of 158 patients with rosacea admitted to the Second Affiliated Hospital of Xi'an Jiaotong University from July 2023 to February 2024 were prospectively selected and divided into the single group(n=79)and the combined group(n=79)according to the single and double number method.The single group was treated with minocycline capsules,100 mg/time,once a day,for 6 weeks.The combined group was treated with rb-bFGF on the basis of single group treatment,rb-bFGF gel 2 times/d,continuous treatment for 6 weeks.The clinical efficacy,the symptom im-provement status(erythema,telangiectasia and papule pustules)before and after 6 weeks of treatment,the skin barrier function[water content of skin stratum corneum,transepidermal water loss(TEWL)and skin pH value]before and after 6 weeks of treatment,the DLQI scores before and after 2,4 and 6 weeks of treatment,and the changes of serum inflammatory factors[interleukin(IL)-6,IL-17A]before and after 6 weeks of treatment were compared between the two groups,and the adverse reactions of the two groups were counted.Results After treatment,the total ef-fective rate of the combined group was 92.41％,which was significantly higher than that of the single group(81.01％),and the difference was statistically significant(P＜0.05).After 6 weeks of treatment,the scores of rosacea symptom in the two groups were significantly lower than those before treatment,and the scores in the combined group were lower than those in the single group,the differences were statistically significant(P＜0.05).After 6 weeks of treatment,the stratum corneum water content and skin pH value of the two groups were significantly higher than those before treatment,and the TEWL value was significantly lower than that before treatment.The stratum corneum water content and skin pH val-ue of the combined group were(48.46±9.07)AU and(5.93±0.37)points,respectively,which were higher than those of the single group[(42.76±8.85)AU,(5.81±0.33)points],the TEWL value was(19.26±3.47)g·h-1·m2,which was lower than that of the single group[(21.52±3.82)g·h-1·m2],and the differences were statistically significant(P＜0.05).After 2,4 and 6 weeks of treatment,the DLQI scores of the two groups were significantly lower than those before treatment,and the DLQI scores of the combined group were significantly lower than those of the single group,the differences were statistically significant(P＜0.05).After 6 weeks of treatment,the levels of IL-6 and IL-17 A in the two groups were significantly lower than those before treatment,and the levels of IL-6 and IL-17 A in the combined group were(29.16±5.97),(23.94±4.49)μg/mL,respectively,which were lower than those in the single group[(32.56±6.40),(26.71±5.41)μg/mL],the differences were statistically significant(P＜0.05).There was no statistically significant difference in the rate of adverse reactions between the combined group and the single group(6.33％vs.5.06％)during treatment(P＞0.05).Conclusion The combination of rb-bF-GF and minocycline is effective in the treatment of rosacea,which can significantly improve the skin condition and inflammatory response and im-prove the patients quality of life,and it is safe and reliable.
维普
万方数据